Evaxion A/S EVAX 深 沪
等待开盘 10-16 09:30:00 美东时间
2.85
+0.050
+1.79%
华盛通- 最 高2.90
- 今 开2.80
- 成交量 1.76万股
- 最 低 2.80
- 昨 收 2.80
- 总市值 2571.12万
- 52周最高 6.92
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 2.72
- 委 比 69.49%
- 总股本 902.15万
- 历史最高 1252.00
- 量 比 0.53
- 振 幅 3.57%
- 历史最低 2.72
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evaxion Expands AI-Immunology Platform into Autoimmune Diseases
Evaxion Biotech ( ($EVAX) ) just unveiled an update. On September 14, 2026, Eva...
09-14 20:35
Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-21 19:10
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at...
08-20 21:34
Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
08-20 19:31
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma
EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05...
08-17 20:03
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented t...
07-17 19:19
Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion")...
07-01 20:01
Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
Evaxion Biotech ( ($EVAX) ) has issued an announcement. On June 11, 2026, Evaxi...
06-11 18:28
